Evidence map›Paper›PMID 30297816›Full record

ArticleClinical and translational gastroenterology2018

Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Novel Potential Biomarker in Gastroenteropancreatic Neuroendocrine Tumors.

Aura D Herrera-Martínez, Manuel D Gahete, Rafael Sánchez-Sánchez, Emilia Alors-Perez, Sergio Pedraza-Arevalo, Raquel Serrano-Blanch, Antonio J Martínez-Fuentes, Maria A Gálvez-Moreno, Justo P Castaño, Raúl M Luque

Open access · goldAbstract read
In one paragraph

Article in Clinical and translational gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Role of the Ghrelin System in Colorectal Cancer.International journal of molecular sciences · 2022
    Review
  4. Review
  5. Article
  6. Oncology letters · 2021
    Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Aura D Herrera-MartínezMaimonides Institute for Biomedical Research of Cordoba (IMIBIC), Córdoba, Spain.
Manuel D GaheteMaimonides Institute for Biomedical Research of Cordoba (IMIBIC), Córdoba, Spain.
Rafael Sánchez-SánchezMaimonides Institute for Biomedical Research of Cordoba (IMIBIC), Córdoba, Spain.
Emilia Alors-PerezMaimonides Institute for Biomedical Research of Cordoba (IMIBIC), Córdoba, Spain.
Sergio Pedraza-ArevaloMaimonides Institute for Biomedical Research of Cordoba (IMIBIC), Córdoba, Spain.
Raquel Serrano-BlanchMaimonides Institute for Biomedical Research of Cordoba (IMIBIC), Córdoba, Spain.
Antonio J Martínez-FuentesMaimonides Institute for Biomedical Research of Cordoba (IMIBIC), Córdoba, Spain.
Maria A Gálvez-MorenoMaimonides Institute for Biomedical Research of Cordoba (IMIBIC), Córdoba, Spain. mariaa.galvez.sspa@juntadeandalucia.es.
Justo P CastañoMaimonides Institute for Biomedical Research of Cordoba (IMIBIC), Córdoba, Spain. justo@uco.es.
Raúl M LuqueMaimonides Institute for Biomedical Research of Cordoba (IMIBIC), Córdoba, Spain. raul.luque@uco.es.
Hospital Universitario Reina Sofía · ESInstituto Maimónides de Investigación Biomédica de Córdoba · ESCentro de Investigación Biomédica en Red · ESUniversity of Córdoba · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe association between the presence and alterations of the components of the ghrelin system and the development and progression of neuroendocrine tumors (NETs) is still controversial and remains unclear.

methodsHere, we systematically evaluated the expression levels (by quantitative-PCR) of key ghrelin system components of in gastroenteropancreatic (GEP)-NETs, as compared to non-tumor adjacent (NTA; n = 42) and normal tissues (NT; n = 14). Then, we analyzed their putative associations with clinical-histological characteristics.

resultsThe results indicate that ghrelin and its receptor GHSR1a are present in a high proportion of normal tissues, while the enzyme ghrelin-O-acyltransferase (GOAT) and the splicing variants In1-ghrelin and GHSR1b were present in a lower proportion of normal tissues. In contrast, all ghrelin system components were present in a high proportion of tumor and NTA tissues. GOAT was significantly overexpressed (by quantitative-PCR (qPCR)) in tumor samples compared to NTA, while a trend was found for ghrelin, In1-ghrelin and GHSR1a. In addition, expression of these components displayed significant correlations with key clinical parameters. The marked overexpression of GOAT in tumor samples compared to NTA regions was confirmed by IHC, revealing that this enzyme is particularly overexpressed in gastrointestinal NETs, where it is directly correlated with tumor diameter.

conclusionsThese results provide novel information on the presence and potential pathophysiological implications of the ghrelin system components in GEP-NETs, wherein GOAT might represent a novel diagnostic biomarker.

Indexed as

AcyltransferasesAdultAgedBiomarkers, TumorCase-Control StudiesCell Line, TumorCell ProliferationDisease ProgressionFemaleGhrelinHumansIntestinal NeoplasmsMaleMiddle AgedNeoplasm GradingNeoplasm StagingAcyltransferasesBiomarkers, TumorGhrelinGHRL protein, humanGhsr1a protein, humanMBOAT4 protein, humanReceptors, Ghrelin

Identifiers

PMID30297816
PMCPMC6175927
OpenAlexW2895965020

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.